Fumaria parviflora Lam. Aqueous Extract Versus Simethicone in the Treatment of Infantile Colic: A Prospective Randomized Clinical Trial

Background: infantile colic observes 10 to 40% of infants during first few months of life. Objectives: The purpose of the present study was to evaluate the effectiveness of Fumaria parviflora Lam. (will fumitory) aqueous extract on infantile colic. Materials and Methods: A total of 52 breastfed infants suffering from infantile colic were randomly assigned to two groups. Will fumitory group and simethicone group received will fumitory extract and simethicone for 10 days, respectively. During the period of study, changing in infants’ colic symptoms including duration of crying, stooling frequency and consistency as well as probable side effects were inquired every day from the parents. Results: The reduction in daily crying duration (<50%) was significantly in will fumitory group (25 vs. 6; p<0.001) as well as cure rate of 100% in this group. There were no significant differences in weight gain, stooling frequency, incidence of constipation, diarrhea and regurgitation between two groups (p>0.05). No adverse effects related to will fumitory and simethicone group were observed. Conclusion: Will fumitory make a considerable improvement in colic related crying in comparison with simethicone. It was also well tolerable by infants suggesting as a new therapeutic approach in infantile colic.